Kymera Therapeutics (KYMR) Insider Booth Sells $65M of Stock

Bruce Booth, a key insider, sold 548,321 shares of Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 25, 2026. The shares were sold at an average price of $118.76 each, totaling about $65.1 million. This transaction was planned under a Rule 10b5-1 trading plan.

Other Institutional Activity in Kymera Therapeutics

FMR LLC increased its holdings in Kymera by 2,771,376 shares, bringing its total to nearly 11.7 million shares valued at about $974.5 million. Meanwhile, T. Rowe Price Investment Management, Inc. significantly boosted its position by 4,835,252 shares, resulting in a total of approximately 5.47 million shares worth $455.2 million. Baker Bros. Advisors LP and Avoro Capital Advisors LLC maintained their existing positions without any changes.

Kymera Therapeutics, Inc. Stock Down 8.2%

Shares of Kymera Therapeutics traded near $99.87 on Friday. The company has a market capitalization of roughly $8.18 billion. It has no meaningful P/E ratio because it isn't currently profitable, with a forward P/E of -22.89. The stock has a 52-week range between $36.65 and $105.00. Its 50-day moving average stands at $83.06, and the 200-day moving average is $73.55.

Insider Buying and Selling at Kymera Therapeutics, Inc.

On June 25, 2026, Bruce Booth executed a planned sale of 548,321 shares at $118.76 per share. On the same day, Noah Goodman, Chief Business Officer, sold 5,000 shares at $114.00 per share and bought 5,000 shares at $21.05 per share outside of a trading plan. Additionally, Gorjan Hrustanovic acquired 6,068 shares on June 24, 2026.

Analysts Set New Price Targets

On June 25, 2026, BTIG reiterated its 'buy' rating for Kymera Therapeutics with a price target of $134. Earlier, Canaccord Genuity initiated coverage with a 'buy' rating and a $106 target on May 6, 2026. The consensus among 21 analysts is a 'strong buy' with an average price target of $119.19.

About Kymera Therapeutics

Kymera Therapeutics, Inc., headquartered in Watertown, Massachusetts, is a biopharmaceutical company focused on developing small molecule therapeutics that degrade disease-causing proteins. The company is involved in various clinical trials, including KT-621 for conditions like atopic dermatitis and KT-579 for autoimmune diseases. With a strategic alliance with Sanofi, Kymera aims to advance its IRAK4 program for immunology-related conditions.

Bottom Line

Bruce Booth's planned sale of Kymera Therapeutics shares underscores the insider activity within the company. Investors closely watch these transactions for potential insights, though they don't necessarily indicate a change in the company's prospects. As always, insider sales are part of the regular trading landscape and may not reflect the current outlook or performance of the company.